Mantle Cell Lymphoma Study for R/R MCL Patients

ACCRU Trial Spotlight

In ACCRU Study LY-1806, principal investigator Dr. Catherine Diefenbach and her team seek to discover whether a new therapy is safe and effective for patients with relapsed mantle cell lymphoma. It has the potential to prolong the survival of R/R MCL patients, including BTK inhibitor-resistant patients, or even have a role in the frontline treatment of elderly or unfit patients who are ineligible for aggressive chemo-immunotherapy. For more information on the study, go here: